CN113993592A - 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物 - Google Patents

针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物 Download PDF

Info

Publication number
CN113993592A
CN113993592A CN202080044361.XA CN202080044361A CN113993592A CN 113993592 A CN113993592 A CN 113993592A CN 202080044361 A CN202080044361 A CN 202080044361A CN 113993592 A CN113993592 A CN 113993592A
Authority
CN
China
Prior art keywords
cancer
mutations
egfr
bosutinib
exon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080044361.XA
Other languages
English (en)
Chinese (zh)
Inventor
J·罗比丘
M·尼尔森
J·V·海马赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN113993592A publication Critical patent/CN113993592A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202080044361.XA 2019-04-17 2020-04-16 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物 Pending CN113993592A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962835343P 2019-04-17 2019-04-17
US62/835,343 2019-04-17
PCT/US2020/028540 WO2020214824A1 (en) 2019-04-17 2020-04-16 Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations

Publications (1)

Publication Number Publication Date
CN113993592A true CN113993592A (zh) 2022-01-28

Family

ID=72837936

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080044361.XA Pending CN113993592A (zh) 2019-04-17 2020-04-16 针对携带酪氨酸激酶抑制剂耐药性egfr突变的癌症的化合物

Country Status (13)

Country Link
US (1) US20220175779A1 (https=)
EP (1) EP3956035A4 (https=)
JP (1) JP7709384B2 (https=)
KR (1) KR20220004089A (https=)
CN (1) CN113993592A (https=)
AU (1) AU2020257395A1 (https=)
BR (1) BR112021020601A2 (https=)
CA (1) CA3132819A1 (https=)
IL (1) IL287115A (https=)
MX (1) MX2021012705A (https=)
PH (1) PH12021552579A1 (https=)
SG (1) SG11202111120VA (https=)
WO (1) WO2020214824A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153256A1 (zh) * 2023-01-16 2024-07-25 威尚（上海）生物医药有限公司 喹唑啉类化合物在克服奥希替尼耐药中的用途

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016149A2 (pt) 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
US11850248B2 (en) 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11879013B2 (en) 2019-05-14 2024-01-23 Janssen Biotech, Inc. Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
JP7783182B2 (ja) 2020-02-12 2025-12-09 ヤンセン バイオテツク，インコーポレーテツド ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療
WO2022165219A1 (en) * 2021-01-29 2022-08-04 Board Of Regents, The University Of Texas System Methods of treating cancer with poziotinib
US20240384350A1 (en) * 2021-01-29 2024-11-21 Board Of Regents, The University Of Texas System Methods of treating cancer with kinase inhibitors
MX2024008057A (es) 2021-12-30 2024-08-28 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017198602A1 (en) * 2016-05-18 2017-11-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2018094225A1 (en) * 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
US20180333415A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3120851A1 (en) * 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
AU2019243738B2 (en) * 2018-03-27 2024-05-30 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations
CA3101657A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
WO2020055643A2 (en) * 2018-09-04 2020-03-19 Rain Therapeutics Inc. Compounds, compositions and methods for treating or preventing her-driven cancers
BR112021016149A2 (pt) * 2019-02-26 2021-10-13 Janssen Biotech, Inc. Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met
MX2021011925A (es) * 2019-03-29 2021-11-03 Univ Texas Compuestos con actividad antitumoral contra celulas cancerigenas que portan inserciones del exon 21 del receptor 2 del factor de crecimiento epidermico humano.
MX2021011948A (es) * 2019-03-29 2022-01-04 Univ Texas Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2.

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017198602A1 (en) * 2016-05-18 2017-11-23 Boehringer Ingelheim International Gmbh Anticancer combination therapy
WO2018094225A1 (en) * 2016-11-17 2018-05-24 Board Of Regents, The University Of Texas System Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
US20180333415A1 (en) * 2017-05-19 2018-11-22 Regents Of The University Of Minnesota Therapeutic methods

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JACQULYNE P. ROBICHAUX等: "Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-selective Kinase Inhibitor in Non-small Cell Lung Cancer", NAT MED., vol. 24, no. 5, pages 638 - 646, XP036901056, DOI: 10.1038/s41591-018-0007-9 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024153256A1 (zh) * 2023-01-16 2024-07-25 威尚（上海）生物医药有限公司 喹唑啉类化合物在克服奥希替尼耐药中的用途
GB2641652A (en) * 2023-01-16 2025-12-10 Weishang Shanghai Bio Pharmaceutical Co Ltd Use of quinazoline compound in overcoming Osimertinib drug resistance

Also Published As

Publication number Publication date
JP7709384B2 (ja) 2025-07-16
IL287115A (en) 2021-12-01
EP3956035A4 (en) 2023-01-25
AU2020257395A1 (en) 2021-11-04
CA3132819A1 (en) 2020-10-22
KR20220004089A (ko) 2022-01-11
US20220175779A1 (en) 2022-06-09
PH12021552579A1 (en) 2022-08-01
EP3956035A1 (en) 2022-02-23
JP2022529945A (ja) 2022-06-27
WO2020214824A1 (en) 2020-10-22
SG11202111120VA (en) 2021-11-29
BR112021020601A2 (pt) 2021-12-07
MX2021012705A (es) 2021-11-12

Similar Documents

Publication Publication Date Title
US20230233563A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 mutations
JP7709384B2 (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがんに対する化合物
JP7822597B2 (ja) チロシンキナーゼ阻害剤耐性ｅｇｆｒ変異を有するがん細胞に対する抗腫瘍活性を有する化合物
WO2019178239A1 (en) Methods for treatment of cancers with egfr activating mutations
AU2019243738B2 (en) Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations
CN113766955A (zh) 对携带her2外显子21插入的癌细胞具有抗肿瘤活性的化合物
HK40064296A (en) Compounds against cancer bearing tyrosine kinase inhibitor resistant egfr mutations
HK40037136A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
HK40064724A (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40064296

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220128

WD01 Invention patent application deemed withdrawn after publication